1. China's CRISPR Breakthrough: New Gene Editing Therapy Targets β-Thalassaemia with Higher Precision
A major Chinese research collaboration has successfully developed an improved CRISPR/Cas9 gene editing system, demonstrating its clinical application in treating β-Thalassaemia. This breakthrough follows the FDA's approval of the first CRISPR-based therapy for sickle-cell anemia just over two years ago, marking a signi...